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Abstract
Background: The germline TP53-R337H mutation is strongly associated with pediatric adrenocortical
tumors (ACT) in southern Brazil; it has low penetrance and limited tissue specificity in most families and
therefore is not associated with Li-Fraumeni syndrome. However, other tumor types, mainly breast
cancer, have been observed in carriers of several unrelated kindreds, raising the possibility that the R337H
mutation may also contribute to breast tumorigenesis in a genetic background-specific context.
Methods: We conducted a case-control study to determine the prevalence of the R337H mutation by
sequencing TP53 exon 10 in 123 women with breast cancer and 223 age- and sex-matched control subjects
from southern Brazil. Fisher's test was used to compare the prevalence of the R337H.
Results: The R337H mutation was found in three patients but in none of the controls (p = 0.0442). Among
the carriers, two had familial history of cancer meeting the Li-Fraumeni-like criteria. Remarkably, tumors
in each of these three cases underwent loss of heterozygosity by eliminating the mutant TP53 allele rather
than the wild-type allele. Polymorphisms were identified within the TP53 (R72P and Ins16) and MDM2
(SNP309) genes that may further diminish TP53 tumor suppressor activity.
Conclusion: These results demonstrate that the R337H mutation can significantly increase the risk of
breast cancer in carriers, which likely depends on additional cooperating genetic factors. These findings
are also important for understanding how low-penetrant mutant TP53 alleles can differentially influence
tumor susceptibility.
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Introduction
Mutations in the TP53 tumor supressor gene usually occur
within the highly conserved DNA-binding domain (aa
100–298) and, when inherited, are typically associated
with Li-Fraumeni syndrome (LFS), in which carriers
develop a broad spectrum of cancers (e.g., breast, brain,
soft tissue, bone, blood, and adrenal cortex tumors) dur-
ing childhood or young adulthood [1]. Families with
incomplete features of LFS are referred to as having Li-
Fraumeni-like (LFL) syndrome [2,3].
In southern Brazil, a unique germline TP53 point muta-
tion resulting in an Arg to His amino acid substitution
(R337H) within the C-terminal oligomerization domain
is strongly associated with childhood adrenocortical
tumors (ACT) [4-6]. Unlike the protypical DNA binding
mutants, p53-R337H retains significant activity, although
its thermal stability is reduced and it is highly sensitive to
slight changes in pH [7]. The R337H mutation has a low
overall malignant potential but is remarkably organ-spe-
cific, affecting mainly the adrenal cortex [4].
In most southern Brazilian families bearing the R337H
mutation, pediatric ACT is the only malignancy observed
[4-6]. However, in about 10–20% of the cases [[6], Sei-
dinger et al., manuscript in preparation] the family cancer
history fulfills the criteria for LFL syndrome with breast
cancer being one of the most common malignancies [6].
Achatz and coworkers [8] identified R337H carriers
among Brazilian LFL families, including one case of breast
carcinoma that underwent loss of the wild-type allele and
retained the mutant allele. These observations suggested
that the R337H mutation may play a role in breast tumor-
igenesis. To test whether the R337H is associated with
breast cancer, we retrospectively examined the prevalence
of the mutation in a group of Brazilian women with breast
cancer.
Methods
Patients and Clinical Data
The study group comprised 123 women with breast can-
cer that had been diagnosed and treated at the Hospital of
the State University of Campinas (CAISM/UNICAMP),
São Paulo, Brazil. The patient's cohort consisted of a sub-
group of women who presented a familial history of
breast cancer (n = 45) and another subgroup consisted of
sporadic breast cancer cases (n = 78). The criteria for the
selection of individuals with familial history were: more
than three cases of breast cancer and more than one case
of ovarian cancer in the family; more than two first-degree
relatives with breast cancer; one case of male breast cancer
[9,10]. Thirty of the 45 patients with positive familial his-
tory were previously tested for BRCA1/2 mutations [11]. A
control group of 223 age-matched female volunteers was
selected among university personnel. Family cancer his-
tory and blood samples were obtained with informed
consent under the guidelines and approval of the Ethical
Research Committees of the Faculty of Medical Sciences
(FCM) at UNICAMP and The Centro Infantil Boldrini,
and the National Committee of Ethics in Research
(CONEP). Aditional clinical information, slides and par-
affin blocks were obtained for those patients who were
shown to carry the R337H mutation.
DNA analysis
Genomic DNA was isolated from peripheral blood by
using a standard phenol-chloroform extraction method
[12]. Paraffin-embedded tumor samples were treated with
xylene-100% ethanol (1:1) and digested with proteinase
K (14 mg/mL) in 50 mmol/L Tris-HCl (pH 8.0) before
phenol-chloroform extraction.
TP53 exon 10 was amplified by using primers and PCR
conditions described by Figueiredo et al. [6], with the
exception of the forward primer used for amplification of
exon 10 DNA from tumor biopsies: 5'-CCATCTTTTAACT-
CAGGTACTG-3'. TP53 intron 3 and exon 4 were ampli-
fied by using primers 5'-
CCCTAGCAGAGACCTGTGGGAA-3' (foward) and 5'-
AGGCATTGAAGTCTCATGGAA-3'(reverse).  TP53  PCR
products were directly sequenced by using the BigDye ter-
minator cycle sequencing ready reaction kit (Applied Bio-
systems, Foster City, CA) in an ABI PRISM 3700 automatic
sequencer (Applied Biosystems). The sequences were
compared to the human TP53  reference sequence
(National Center for Biotechnology Information, acces-
sion number U94788). All mutations were confirmed by
a second, independent analysis. Tumor DNA was also
screened for TP53 alterations in other exons and introns
where technically feasible, essentially as previously
described [13]. In cases heterozygous for codon 72 and
ins16, haplotypes were determined by performing an
allele-specific PCR assay as described by Osorio et al. [14].
The  MDM2  promoter was amplified with primers
described by Bond et al. [15] and PCR products were ana-
lyzed by restriction fragment length polymorphism as
described by Walsh et al. [16].
Immunohistochemistry
Expression of p53 protein was examined by immunohis-
tochemistry with the DO7 monoclonal antibody (Dako)
at 1:100 dilution. The slides were incubated with Envision
labeled polymer components (Dako, K1491) and devel-
oped with 3-3-diaminobenzidine (Sigma, D5637). Tissue
from borderline ovarian tumors was included in each
assay as a positive control for p53. Slides were interpreted
at 40× magnification by a single pathologist. p53 protein
expression was considered positive when more than 10%
of the nuclei were stained; staining intensity was not con-
sidered.BMC Cancer 2008, 8:357 http://www.biomedcentral.com/1471-2407/8/357
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Statistical analysis
Fisher's exact test (FREQ procedures in SAS v9.1.3, SAS
Institute Inc., Cary, NC) was used to compare the fre-
quency of the R337H mutation in the breast cancer and
control groups. The R337H mutation rate in the breast
cancer group was estimated and the 95% exact CI
reported. This rate was compared to the estimated popu-
lation frequency of the mutation (assumed to be the true
prevalence rate for the population) in the region of inter-
est in southern Brazil by using the one-sided exact test for
binomial proportion.
Results
Identification of the germline R337H TP53 mutation in 
breast cancer patients
The R337H mutation was detected in the germline DNA
of three of 123 breast cancer patients in southern Brazil.
None of the 223 control subjects carried the R337H muta-
tion or any other mutation in TP53 exon 10. There was a
significant association between the presence of the R337H
mutation and breast cancer (p = 0.0442; Fisher's exact test,
Table 1). The mutation rate of R337H in the cancer-posi-
tive group was 2.4%, with an exact Blyth-Still-Casella 95%
CI of 0.7% to 6.6%. The overall frequency of the R337H
in the region of interest in southern Brazil is assumed to
be in the range 0.2%–0.3% [[17], B. Figueiredo, personal
communication]. Therefore, the frequency of the R337H
mutation was significantly greater among patients with
breast cancer than in the general population of the region
(p = 0.002 and 0.006 in comparison to a population prev-
alence rate of 0.2% and 0.3%, respectively; one-sided
exact binomial test).
Family cancer history
Table 2 summarizes clinical findings for the three carriers
of the R337H mutation. All three developed breast cancer
at an early age (19, 29, and 44 years). Patient 2 had a sec-
ond cancer (brain tumor) at the age of 31 years. Patient 1
had no familial history of cancer. Patient 2 had two first-
degree relatives with cancer; although the tumor type and
age of onset were not known, this family might fulfill LFL-
syndrome criteria. Patient 3's family cancer history met
Birch's criteria [2] for LFL: a mother with bilateral breast
cancer at age 53, three maternal aunts with post-meno-
pausal breast-cancer, a sister with leukemia at age 48, and
a grandson with adrenocortical carcinoma at age 18
months.
Selection against the mutant TP53 R337H allele during 
breast tumorigenesis
Tumors with a germline or somatic TP53 mutation usu-
ally experience loss of heterozygosity (LOH) in which the
wild-type allele is deleted or mutated. Surprisingly, the
mutant R337H allele was deleted in all three of the stud-
ied breast tumors. No somatic mutations were detected
within sequences that could be determined (exons 2, 4, 5,
7, 8, 9, and 10) in any of the breast tumors. By contrast,
the brain tumor of patient 2 was homozygous for the
R337H TP53  mutation, it also had a second, acquired
mutation (T125M), in the DNA binding domain.
Tumor expression of p53 protein
R337H-mutant protein accumulates within the nuclei of
ACT cells and is detectable by immunohistochemistry, as
is other missense mutant p53 expressed in tumors [4].
Breast tumor tissue from patients 1 and 2 was negative for
nuclear p53, consistent with selection against the mutant
allele. However, breast tumor tissue from patient 3
expressed nuclear p53. Because this tumor had deleted the
mutant allele (Table 2), this finding implies that a somatic
TP53 mutation outside of exon 10 was acquired during
tumorigenesis. However, insufficient tumor tissue hin-
dered the identification of this genetic alteration. The
brain tumor tissue from patient 2 also stained positive for
nuclear p53, consistent with retention of the allele encod-
ing 337H and acquisition of a second-site mutation
(T125M) within the DNA binding domain (See addi-
tional file 1: IHC and LOH results of tumor samples from
R337H patients).
Polymorphisms associated with the R337H mutation and 
breast cancer
To investigate whether TP53 polymorphisms were associ-
ated with the R337H mutation in the three breast tumor
patients, we tested for two common TP53 variants (R72P
and ins16) reported to affect breast cancer susceptibility
[18-21]. Patients 1 and 3 were heterozygous in the germ-
line for both the R72P and ins16. Patient 2 was
homozygous for R72 and negative for ins16 (Table 3). In
the tumor tissue of patients 1 and 3, codon 72 encoded
only arginine, indicating a selection against the proline
allele.
Due to early age of tumor onset, patient 1 was also tested
for BRCA1/2 (data not shown) and a polymophic change
Table 1: Relation of the R337H TP53 mutation to breast cancer status
Gene Codon Genotype Cases (%) Controls (%) P value
TP53 337 Arg/Arg 120 (97.6%) 223 (100%) 0.0442
Arg/His 3 (2.4%) 0BMC Cancer 2008, 8:357 http://www.biomedcentral.com/1471-2407/8/357
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was detected at BRCA2 exon 10 (N372H). The other two
R337H carriers were not screened for BRCA1/2 mutations.
We also investigated the presence of the SNP309-G within
the first intron of the MDM2 gene, which is a key negative
regulator of p53 protein [22]. SNP309-G has been
reported to accelerate tumor formation in carriers of a
TP53 mutation [15]. Patients 1 and 2 were heterozygous
for SNP309-G (G/T) and patient 3 was homozygous for
the T allele (T/T) (Table 3).
Discussion
Our findings show that the germline TP53 R337H muta-
tion is associated with breast cancer in southern Brazil
within the context of LFL-like families and a sporadic case.
In our case-control study, three (2.4%) breast cancer
patients, but none of the age-matched control subjects,
carried this mutation. This frequency is approximately 10
times that estimated in the general southern Brazilian
population (0.2% to 0.3%; p = 0.0221) [[17], B. Figueir-
edo, personal communication].
Germline TP53 mutations are estimated to occur in no
more than 0.25% of patients with breast tumors, regard-
less of family history [23-25]. Therefore, the R337H muta-
tion is the most common inherited TP53  mutation
associated with breast cancer in southern Brazil. It is also
the most frequently reported germline mutation in the
International Agency for Research on Cancer database
[26,27], predominantly because of its association with
most pediatric ACT cases (~80%–95%) in southern Brazil
[4,5]. However, the high incidence of breast cancer in this
region is unlikely to be solely attributable to the R337H
TP53 mutation, as only 2.4% of women with breast cancer
in this cohort carried the mutation.
It remains unclear how the R337H mutation contributes
to breast tumorigenesis. Remarkably, all three tumors
selected against the mutant allele and retained the wild-
type allele. In striking contrast, virtually all pediatric ACTs
found to be associated with a germline R337H mutation
had selected against the wild-type allele [4,5], including
that of the grandson of patient 3 (data not shown). These
results suggest that the mechanism of R337H-associated
ACT tumorigenesis differs from that of R337H-associated
breast cancer. The R337H mutation appears to play a role
in accelerating the onset of breast tumorigenesis, but may
not affect tumor progression in some individuals, how-
ever further studies are required to clarify this matter.
Many families that carry the germline R337H mutation
are selectively predisposed to childhood ACT [4,6],
although some appear to be at higher risk of more diverse
cancers, including breast tumors and possibly other LF
spectrum neoplasms such as brain tumors. Indeed, the
R337H has been detected in LFL syndrome cases [8], but
these represent the minority of the families positive for
R337H [[6], Seidinger et al., manuscript in preparation].
We believe that the cancer predisposing character of low-
Table 2: Clinical findings and family cancer history of the three TP53 R337H carriers
Patient Tumor Type Age Onset TP53 IHC Family Cancer History
1 Breast; phyllodes, malignant 19 years Negative No cancer
2 Breast; invasive ductal carcinoma
Brain tumor (malignant)
29 years
31 years
Negative
Positive
Two first-degree relatives (1-U; 1-A)
3 Invasive ductal carcinoma 44 years Positive Six first-degree relatives (4-BC; 1-L; 1-ACC)
IHC = immunohistochemistry, U = uterus, A = arm (unknown type of cancer), BC = breast cancer, L = leukemia, ACC = adrenocortical carcinoma
Table 3: Germline and tumor genotype of TP53 and MDM2
Patient DNA Sample TP53 c 337 TP53 c72 TP53 Ins16 TP53 Haplotypes MDM2-309
1 Blood Arg/His Arg/Pro Ins+/Ins- Arg;ins-/Pro;ins+ T/G
Breast Tumor Arg Arg
2 Blood Arg/His Arg/Arg Ins-/Ins- Arg;ins-/Arg;ins- T/G
Breast Tumor Arg Arg
Brain Tumor His Arg
3 Blood Arg/His Arg/Pro Ins+/Ins- Arg;ins-/Pro;ins+ T/T
Breast Tumor Arg ArgBMC Cancer 2008, 8:357 http://www.biomedcentral.com/1471-2407/8/357
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penetrant TP53 mutations, such as R337H, depends on
additional genetic modifiers.
Our observations of TP53  polymorphisms (R72P and
ins16) and MDM2  (SNP309) are consistent with this
hypothesis. Two out of the three R337H positive patients
were heterozygous for the R72P and ins16 polymor-
phisms (Table 3). Although the consequence of these pol-
ymorphisms is controversial, proline-72 is proposed to
function less well in triggering apoptosis and tumor sup-
pression [28]. Likewise, ins16 within intron 3 diminishes
TP53 expression [29] and has been implicated in ovarian
and breast cancer [18,30,19,31]. Patients 1 and 2 who
were 19 and 29 years old at diagnosis, respectively, were
heterozygous for MDM2 SNP309 (G/T), while patient 3
who was 44 years old at diagnosis, was homozygous for
the T allele (T/T). These findings are in line with previous
reports showing that individuals carrying a TP53 germline
mutation who are heterozygous or homozygous for
SNP309-G develop tumors on average 10 years earlier
than carriers of TP53  mutations who lack SNP309
[15,32]. Moreover, patient 1 also carries the N372H poly-
morphism at BRCA2 exon 10, which might contribute to
breast tumorigenesis [33].
It is possible that the R337H mutation in combination
with these polymorphisms and possibly other genetic
alterations creates a p53-insufficient state that enhances
tumor susceptibility. The degree of p53 function retained
by a particular mutant and influenced by genetic modifi-
ers within its signaling pathway dictates the level of tumor
risk, which we refer to as the TP53 gradient effect [34].
In conclusion, we showed that the TP53R337H mutation
is significantly associated with breast cancer in southern
Brazil. However, this mutation is likely to account for only
a small proportion of breast cancer cases in this region.
Our results illustrate the complexity of constitutional pre-
disposition to cancer, including that associated with TP53
mutations. A rigorous family history of cancer, p53 pre-
dicted functional characteristics, the presence of other
genetic modifiers, and examination of the tumor cells for
loss of heterozygosity must be considered in risk assess-
ment analysis and genetic counseling.
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